688198 佰仁医疗
已收盘 12-18 15:00:00
资讯
新帖
简况
佰仁医疗（688198）新增【医美】概念
证券之星 · 12-12
佰仁医疗（688198）新增【医美】概念
佰仁医疗(688198.SH)：胶原蛋白植入剂产品获批注册 是国内首款用于面颊部真皮层注射以改善面颊部平滑度的胶原蛋白产品
智通财经 · 12-11
佰仁医疗(688198.SH)：胶原蛋白植入剂产品获批注册 是国内首款用于面颊部真皮层注射以改善面颊部平滑度的胶原蛋白产品
佰仁医疗(688198.SH)：ePTFE心包膜产品获批注册
智通财经 · 12-03
佰仁医疗(688198.SH)：ePTFE心包膜产品获批注册
每周股票复盘：佰仁医疗（688198）股东户数增15.65%，Q3净利降9.39%
证券之星 · 11-02
每周股票复盘：佰仁医疗（688198）股东户数增15.65%，Q3净利降9.39%
佰仁医疗（688198）2025年三季报简析：营收净利润同比双双增长，公司应收账款体量较大
证券之星 · 11-01
佰仁医疗（688198）2025年三季报简析：营收净利润同比双双增长，公司应收账款体量较大
图解佰仁医疗三季报：第三季度单季净利润同比下降9.39%
证券之星 · 10-30
图解佰仁医疗三季报：第三季度单季净利润同比下降9.39%
佰仁医疗(688198)9月30日股东户数0.4万户，较上期增加15.65%
证券之星 · 10-30
佰仁医疗(688198)9月30日股东户数0.4万户，较上期增加15.65%
佰仁医疗：选举第三届董事会职工代表董事
证券日报 · 09-25
佰仁医疗：选举第三届董事会职工代表董事
佰仁医疗(688198.SH)：射频消融系统进入创新医疗器械特别审查程序
智通财经 · 09-23
佰仁医疗(688198.SH)：射频消融系统进入创新医疗器械特别审查程序
每周股票复盘：佰仁医疗（688198）取消监事会获股东高票通过
证券之星 · 09-21
每周股票复盘：佰仁医疗（688198）取消监事会获股东高票通过
佰仁医疗（688198）披露取消公司监事会及修订公司章程公告，9月17日股价上涨0.07%
证券之星 · 09-17
佰仁医疗（688198）披露取消公司监事会及修订公司章程公告，9月17日股价上涨0.07%
每周股票复盘：佰仁医疗（688198）拟取消监事会并变更注册资本
证券之星 · 09-14
每周股票复盘：佰仁医疗（688198）拟取消监事会并变更注册资本
佰仁医疗(688198)6月30日股东户数0.34万户，较上期增加10.55%
证券之星 · 08-28
佰仁医疗(688198)6月30日股东户数0.34万户，较上期增加10.55%
佰仁医疗：2025年上半年净利润同比增长102.90%
金融界 · 08-27
佰仁医疗：2025年上半年净利润同比增长102.90%
医疗器械行业行业研究：脑机接口行业深度：政策+创新双轮驱动，商业化落地进入快车道
国金证券 · 08-10
医疗器械行业行业研究：脑机接口行业深度：政策+创新双轮驱动，商业化落地进入快车道
佰仁医疗涨5.20% 政策红利与估值修复预期提振股价
智选洞察 · 08-04
佰仁医疗涨5.20% 政策红利与估值修复预期提振股价
佰仁医疗股价下跌2.52% 总市值145.16亿元
金融界 · 08-01
佰仁医疗股价下跌2.52% 总市值145.16亿元
佰仁医疗35万限售股7月29日将流通
瑞财经 · 07-24
佰仁医疗35万限售股7月29日将流通
多家跨国医疗巨头奔赴链博会，本土药械供应链再升级
第一财经 · 07-16
多家跨国医疗巨头奔赴链博会，本土药械供应链再升级
佰仁医疗主力两日净流出131.7万 高估值或压股价
智选洞察 · 07-04
佰仁医疗主力两日净流出131.7万 高估值或压股价
暂无数据
公司概况
公司名称：
北京佰仁医疗科技股份有限公司
所属行业：
专用设备制造业
上市日期：
2019-12-09
主营业务：
北京佰仁医疗科技股份有限公司的主营业务是医疗器械的研发、生产、销售及服务。公司的主要产品是动物源性植介入医疗器械。
发行价格：
23.68
{"stockData":{"symbol":"688198","market":"SH","secType":"STK","nameCN":"佰仁医疗","latestPrice":112.92,"timestamp":1766041200000,"preClose":114.59,"halted":0,"volume":262025,"delay":0,"changeRate":-0.0146,"floatShares":138000000,"shares":138000000,"eps":1.3092,"marketStatus":"已收盘","change":-1.67,"latestTime":"12-18 15:00:00","open":114.5,"high":114.79,"low":112,"amount":29742900,"amplitude":0.0243,"askPrice":112.92,"askSize":1,"bidPrice":112.9,"bidSize":2,"shortable":0,"etf":0,"ttmEps":1.3092,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766107800000},"marketStatusCode":5,"adr":0,"adjPreClose":114.59,"symbolType":"stock_kcb","openAndCloseTimeList":[[1766021400000,1766028600000],[1766034000000,1766041200000]],"highLimit":126.05,"lowLimit":103.13,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":137748133,"isCdr":false,"pbRate":12.49,"roa":"--","peRate":86.251146,"roe":"7.39%","epsLYR":1.07,"committee":-0.050847,"marketValue":15555000000,"turnoverRate":0.0019,"status":1,"afterMarket":{"amount":0,"volume":0,"close":112.92,"buyVolume":0,"sellVolume":0,"time":1766043237768,"indexStatus":"已收盘 12-18 15:30:00","preClose":114.59},"floatMarketCap":15555000000},"requestUrl":"/m/hq/s/688198/tweets","defaultTab":"tweets","newsList":[{"id":"2590654506","title":"佰仁医疗（688198）新增【医美】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2590654506","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590654506?lang=zh_cn&edition=full","pubTime":"2025-12-12 20:30","pubTimestamp":1765542623,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，12月12日佰仁医疗新增概念。佰仁医疗主营业务：公司是国内技术领先的、专注于动物源性植介入医疗器械研发与生产的高新技术企业,产品应用于心脏瓣膜置换与修复、先天性心脏病植介入治疗以及外科软组织修复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200037119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2590389595","title":"佰仁医疗(688198.SH)：胶原蛋白植入剂产品获批注册 是国内首款用于面颊部真皮层注射以改善面颊部平滑度的胶原蛋白产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2590389595","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590389595?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:22","pubTimestamp":1765441360,"startTime":"0","endTime":"0","summary":"智通财经APP讯，佰仁医疗 发布公告，近日，经国家药品监督管理局审评，公司控股子公司北京艾佰瑞生物技术有限公司胶原蛋白植入剂产品注册申请获得批准，这是国内首款用于面颊部真皮层注射以改善面颊部平滑度的胶原蛋白产品。鉴于该产品为全长胶原蛋白分子，确保了其三螺旋结构的完整性;同时，高纯度满足了产品自发组装成胶原纤维，致使这款产品在结构和品质上不同于以往同类注射用胶原蛋白。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"佰仁医疗(688198.SH)：胶原蛋白植入剂产品获批注册 是国内首款用于面颊部真皮层注射以改善面颊部平滑度的胶原蛋白产品","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2588012321","title":"佰仁医疗(688198.SH)：ePTFE心包膜产品获批注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2588012321","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588012321?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:46","pubTimestamp":1764755172,"startTime":"0","endTime":"0","summary":"智通财经APP讯，佰仁医疗 发布公告，近日，经国家药品监督管理局审查，公司研发的心包膜产品获批注册。目前国内市场所用的心包膜为外企垄断，长期以来依赖进口，该产品的注册和上市将结束心外ePTFE心包膜依赖进口的历史。基于庞大的治疗需求，国内心脏大血管外科手术量多年来保持持续增长，2024年全国心外科总手术量约36万例，公司ePTFE心包膜产品具有广阔的应用前景，也将使更多患者受益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"佰仁医疗(688198.SH)：ePTFE心包膜产品获批注册","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2580474384","title":"每周股票复盘：佰仁医疗（688198）股东户数增15.65%，Q3净利降9.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580474384","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580474384?lang=zh_cn&edition=full","pubTime":"2025-11-02 05:39","pubTimestamp":1762033154,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，佰仁医疗报收于114.55元，较上周的106.55元上涨7.51%。本周，佰仁医疗10月29日盘中最高价报116.0元。佰仁医疗当前最新总市值157.79亿元，在医疗器械板块市值排名17/126，在两市A股市值排名1202/5163。本周关注点股本股东变化：截至2025年9月30日股东户数为3962户，较6月30日增加536户，增幅15.65%。业绩披露要点：2025年第三季度归母净利润2129.63万元，同比下降9.39%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2580541781","title":"佰仁医疗（688198）2025年三季报简析：营收净利润同比双双增长，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2580541781","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580541781?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:48","pubTimestamp":1761950931,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期佰仁医疗发布2025年三季报。截至本报告期末，公司营业总收入3.82亿元，同比上升30.58%，归母净利润9269.69万元，同比上升57.93%。本报告期佰仁医疗公司应收账款体量较大，当期应收账款占最新年报归母净利润比达94.63%。去年的净利率为26.33%，算上全部成本后，公司产品或服务的附加值高。持有佰仁医疗最多的基金为圆信永丰聚优股票A，目前规模为5.58亿元，最新净值1.2968，较上一交易日下跌1.17%，近一年上涨38.56%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100007843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198"],"gpt_icon":0},{"id":"2579145915","title":"图解佰仁医疗三季报：第三季度单季净利润同比下降9.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579145915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579145915?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:46","pubTimestamp":1761824805,"startTime":"0","endTime":"0","summary":"证券之星消息，佰仁医疗2025年三季报显示，前三季度公司主营收入3.82亿元，同比上升30.58%；归母净利润9269.69万元，同比上升57.93%；扣非净利润8011.52万元，同比上升44.84%；其中2025年第三季度，公司单季度主营收入1.34亿元，同比上升31.54%；单季度归母净利润2129.63万元，同比下降9.39%；单季度扣非净利润1871.69万元，同比下降17.72%；负债率17.09%，投资收益669.71万元，财务费用-59.01万元，毛利率88.17%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000040317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198"],"gpt_icon":0},{"id":"2579118329","title":"佰仁医疗(688198)9月30日股东户数0.4万户，较上期增加15.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579118329","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579118329?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:28","pubTimestamp":1761816501,"startTime":"0","endTime":"0","summary":"证券之星消息，近日佰仁医疗披露，截至2025年9月30日公司股东户数为3962.0户，较6月30日增加536.0户，增幅为15.65%。在医疗器械行业个股中，佰仁医疗股东户数低于行业平均水平，截至9月30日，医疗器械行业平均股东户数为2.21万户。从股价来看，2025年6月30日至2025年9月30日，佰仁医疗区间涨幅为3.03%，在此期间股东户数增加536.0户，增幅为15.65%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000033126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2570016051","title":"佰仁医疗：选举第三届董事会职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2570016051","media":"证券日报 ","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570016051?lang=zh_cn&edition=full","pubTime":"2025-09-25 22:06","pubTimestamp":1758809160,"startTime":"0","endTime":"0","summary":"证券日报网讯 9月25日晚间，佰仁医疗发布公告称，公司于2025年9月25日在公司会议室召开2025年职工代表大会，审议通过了《关于选举公司第三届董事会职工代表董事的议案》，同意选举李丽艳女士为公司第三届董事会职工代表董事。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-25/doc-infrtpuk1050096.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-25/doc-infrtpuk1050096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2569036798","title":"佰仁医疗(688198.SH)：射频消融系统进入创新医疗器械特别审查程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2569036798","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569036798?lang=zh_cn&edition=full","pubTime":"2025-09-23 16:40","pubTimestamp":1758616830,"startTime":"0","endTime":"0","summary":"智通财经APP讯，佰仁医疗(688198.SH)发布公告，近日，公司自主研发的射频消融系统获国家药品监督管理局医疗器械技术审评中心同意，进入创新医疗器械特别审查程序。该射频消融系统由消融仪、消融钳和消融笔三个产品组成，专用于心外科手术治疗持续性、永久性房颤。该产品是按照传统迷宫手术原理，采用心外直视手术的方式，对心房组织进行电隔离，即创建透壁、连续、不可逆的线性损伤，从而达到消除房颤触发灶和维持基质，以达到恢复窦性心律的目的。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1348461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688198","BK1583","159883","BK1100","BK1222","BK0251","BK1574","09996","09997"],"gpt_icon":0},{"id":"2569324954","title":"每周股票复盘：佰仁医疗（688198）取消监事会获股东高票通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2569324954","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569324954?lang=zh_cn&edition=full","pubTime":"2025-09-21 05:17","pubTimestamp":1758403035,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘，佰仁医疗报收于108.02元，较上周的111.76元下跌3.35%。本周，佰仁医疗9月16日盘中最高价报114.7元。本周关注点公司公告汇总：佰仁医疗2025年第一次临时股东大会审议通过取消监事会的议案，出席股东代表股份占总股本69.3663%。表决程序合法，议案均获通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100001383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2568464245","title":"佰仁医疗（688198）披露取消公司监事会及修订公司章程公告，9月17日股价上涨0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568464245","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568464245?lang=zh_cn&edition=full","pubTime":"2025-09-17 17:34","pubTimestamp":1758101689,"startTime":"0","endTime":"0","summary":"截至2025年9月17日收盘，佰仁医疗报收于113.16元，较前一交易日上涨0.07%，最新总市值为155.88亿元。近日，佰仁医疗发布2025年第一次临时股东大会决议公告，会议审议通过了《关于取消公司监事会的议案》《关于变更公司注册资本、修订<公司章程>并办理工商变更登记的议案》等多项议案。公告显示，本次股东大会于2025年9月16日以现场和网络投票方式召开，出席会议的股东及代理人共40人，代表有表决权股份95,550,844股，占公司总股本的69.3663%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700030550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2567013687","title":"每周股票复盘：佰仁医疗（688198）拟取消监事会并变更注册资本","url":"https://stock-news.laohu8.com/highlight/detail?id=2567013687","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567013687?lang=zh_cn&edition=full","pubTime":"2025-09-14 04:29","pubTimestamp":1757795351,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，佰仁医疗报收于111.76元，较上周的109.0元上涨2.53%。本周关注点公司公告汇总：佰仁医疗拟取消监事会，其职权由董事会审计委员会行使公司公告汇总：因限制性股票归属，公司股份总数增至13,774.8133万股，注册资本增至137,748,133元公司公告汇总：佰仁医疗将于2025年9月16日召开临时股东大会审议多项议案公司公告汇总佰仁医疗2025年第一次临时股东大会会议资料北京佰仁医疗科技股份有限公司将于2025年9月16日召开2025年第一次临时股东大会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400001015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2562082309","title":"佰仁医疗(688198)6月30日股东户数0.34万户，较上期增加10.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562082309","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562082309?lang=zh_cn&edition=full","pubTime":"2025-08-28 17:27","pubTimestamp":1756373243,"startTime":"0","endTime":"0","summary":"证券之星消息，近日佰仁医疗披露，截至2025年6月30日公司股东户数为3426.0户，较3月31日增加327.0户，增幅为10.55%。在医疗器械行业个股中，佰仁医疗股东户数低于行业平均水平，截至6月30日，医疗器械行业平均股东户数为2.21万户。从股价来看，2025年3月31日至2025年6月30日，佰仁医疗区间跌幅为3.68%，在此期间股东户数增加327.0户，增幅为10.55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800033142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2562741650","title":"佰仁医疗：2025年上半年净利润同比增长102.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562741650","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562741650?lang=zh_cn&edition=full","pubTime":"2025-08-27 20:58","pubTimestamp":1756299488,"startTime":"0","endTime":"0","summary":"佰仁医疗公告，2025年上半年营业收入2.48亿元，同比增长30.07%。净利润7140.06万元，同比增长102.90%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/27205852754007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688198"],"gpt_icon":0},{"id":"2558835566","title":"医疗器械行业行业研究：脑机接口行业深度：政策+创新双轮驱动，商业化落地进入快车道","url":"https://stock-news.laohu8.com/highlight/detail?id=2558835566","media":"国金证券","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558835566?lang=zh_cn&edition=full","pubTime":"2025-08-10 12:06","pubTimestamp":1754798792,"startTime":"0","endTime":"0","summary":"投资逻辑国内政策叠加资本双重支持，行业迎来重大发展机遇。近年来国内政策端对脑机接口行业支持力度较高，支持性政策在产品注册、医保支付、行业标准等层面均有体现。1）在产品注册方面，国家药监局将配合相关部门出台基于脑机接口技术的医疗器械产品支持政策，脑机接口相关产品有望通过创新器械绿色通道实现更快注册审批。其中医疗健康领域仍是脑机接口应用最大的细分领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081012063594da7295&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081012063594da7295&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688677","688410","603976","600645","688314","603387","688253","688581","688617","688755","688075","688198","688212","688277","688366","688085","688606","603658","688161","688613","688067","688139","688351","688273","688301","600587","688426","688656","688050","603205","688029","688151","688016","603880","159883","600529","688114","688289","688358","688575","603309","603014","688013","688317","688193","688298","688393","688338","688468","688607","688767","688108","688217","688580","688026","688389","688576","688271","600055","605369","688236","603987","688068","603222","560260","600807"],"gpt_icon":0},{"id":"2556870540","title":"佰仁医疗涨5.20% 政策红利与估值修复预期提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=2556870540","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556870540?lang=zh_cn&edition=full","pubTime":"2025-08-04 13:07","pubTimestamp":1754284064,"startTime":"0","endTime":"0","summary":"佰仁医疗股价今日表现强势，截至13点07分，佰仁医疗上涨5.20%，最新价报114.99元/股。资金博弈与市场风格共振引发波动近期佰仁医疗净流入与资金面高频切换密切相关。公司动态市盈率达92.89倍，显著高于医疗器械板块平均水平，估值分歧引发机构调仓动作。技术面显示，年初至今股价已修复6.27%，动态市盈率处于近三年低位，叠加政策红利释放预期，中长期估值中枢有望稳步抬升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804130748a6d19449&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804130748a6d19449&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2556855412","title":"佰仁医疗股价下跌2.52% 总市值145.16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556855412","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556855412?lang=zh_cn&edition=full","pubTime":"2025-08-01 03:51","pubTimestamp":1753991515,"startTime":"0","endTime":"0","summary":"佰仁医疗7月31日股价报收105.38元，较前一交易日下跌2.72元。当日成交量为7206手，成交金额达0.77亿元。该公司主营业务为心脏瓣膜等高端医疗器械的研发、生产和销售。作为一家专注于心血管疾病治疗领域的企业，其产品线涵盖人工生物心脏瓣膜、瓣膜成形环等产品。从资金流向来看，当日主力资金净流出116.68万元。公司当前市盈率为111.65倍，市净率达到12.28倍。风险提示：股市有风险，投资需谨慎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080104004094c7065e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080104004094c7065e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2553016392","title":"佰仁医疗35万限售股7月29日将流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2553016392","media":"瑞财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553016392?lang=zh_cn&edition=full","pubTime":"2025-07-24 18:26","pubTimestamp":1753352795,"startTime":"0","endTime":"0","summary":"近日，佰仁医疗传来振奋消息。2025年7月23日，公司顺利完成2020年限制性股票激励计划首次授予部分第五个归属期、预留授予部分第三个归属期的股份登记工作。此次上市流通的股票总数达35万股，将于2025年7月29日正式上市流通。本次激励计划覆盖107位激励对象，其中首次授予部分涉及65人，预留授予部分涉及44人。从业绩表现来看，2025年一季度，佰仁医疗展现出强劲的发展态势，实现收入1.00亿元，归母净利润达到3250万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724182639971bce09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724182639971bce09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2551662190","title":"多家跨国医疗巨头奔赴链博会，本土药械供应链再升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2551662190","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551662190?lang=zh_cn&edition=full","pubTime":"2025-07-16 00:15","pubTimestamp":1752596100,"startTime":"0","endTime":"0","summary":"第一财经记者获悉，即将于7月16日开幕的第三届中国国际供应链促进博览会，包括美敦力、阿斯利康、GE医疗等跨国医疗巨头确认参展。美敦力方面介绍，今年是该公司首次参加链博会，并将展示一款全新的由美敦力中国研发中心和本土临床专家合作的起搏心脏导管研发成果。在本届链博会上，阿斯利康国际市场供应链管理高级执行总裁Steven Rota也将发表主旨演讲。阿斯利康已连续第三年参加链博会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716062402a44d2312&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716062402a44d2312&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688677","688410","603976","688626","600645","688314","603387","688253","688581","688617","688755","688075","688198","688212","688366","688085","688606","603658","688161","688613","688067","688139","688351","688273","688301","600587","688426","688656","603301","688050","603205","688029","688151","688016","603880","600529","688114","688289","688358","688575","603309","603014","688013","688317","688399","688193","159891","688298","688338","688393","688468","688607","688767","688108","688217","688580","688026","688389","688576","688271","600055","605369","688236","603987","688068","603222","600807"],"gpt_icon":0},{"id":"2548350783","title":"佰仁医疗主力两日净流出131.7万 高估值或压股价","url":"https://stock-news.laohu8.com/highlight/detail?id=2548350783","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548350783?lang=zh_cn&edition=full","pubTime":"2025-07-04 15:24","pubTimestamp":1751613876,"startTime":"0","endTime":"0","summary":"佰仁医疗今日主力资金净流出99.8万元，上一交易日主力净流出31.9万元。估值压力与市场迁移形成资金博弈近期佰仁医疗主力资金呈现多空交替，截至7月4日收盘，其动态市盈率达106.48倍，显著高于医疗器械行业平均水平，高估值引发部分资金选择阶段性兑现。技术壁垒与政策红利构建成长护城河佰仁医疗在心脏瓣膜领域的核心技术积累形成差异化壁垒，2024年前三季度实现营收3.8亿元，华东、华南两大核心市场合计贡献58.79%收入，区域渠道优势持续巩固。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704152746a4ceeaf8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704152746a4ceeaf8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688198"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766076585394,"stockEarnings":[{"period":"1week","weight":-0.017},{"period":"1month","weight":-0.0751},{"period":"3month","weight":0.0454},{"period":"6month","weight":0.1114},{"period":"1year","weight":-0.0134},{"period":"ytd","weight":0.0437}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0161},{"period":"3month","weight":0.0147},{"period":"6month","weight":0.1537},{"period":"1year","weight":0.1461},{"period":"ytd","weight":0.1565}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京佰仁医疗科技股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"3962人(较上一季度增加15.65%)","perCapita":"34767股","listingDate":"2019-12-09","address":"北京市昌平区科技园东区华昌路2号","registeredCapital":"13774万元","survey":" 北京佰仁医疗科技股份有限公司的主营业务是医疗器械的研发、生产、销售及服务。公司的主要产品是动物源性植介入医疗器械。","listedPrice":23.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"佰仁医疗(688198)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供佰仁医疗(688198)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"佰仁医疗,688198,佰仁医疗股票,佰仁医疗股票老虎,佰仁医疗股票老虎国际,佰仁医疗行情,佰仁医疗股票行情,佰仁医疗股价,佰仁医疗股市,佰仁医疗股票价格,佰仁医疗股票交易,佰仁医疗股票购买,佰仁医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"佰仁医疗(688198)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供佰仁医疗(688198)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}